SFTs are mesenchymal tumors, now considered a variant of hemangiopericytomas.[
2] They arise most frequently in the pleura. However, occurrences of these tumors at sites other than the pleura have been described in recent years. Extrapleural tumors have occurred in the upper respiratory tract, lung, nasal cavity, paranasal sinuses, orbits, mediastinum, major salivary glands, breast, meninges, liver, and urogenital organs.[
3] The origin of most cases of SFT of the kidney is difficult to determine and may originate from the renal capsule,[
4] interstitial tissues, or peripelvic connective tissues.
Seventy percent of SFTs express CD 34, CD99, and Bcl-2; only 20 to 35% are variably positive for epithelial membrane antigen and smooth muscle actin. Focal and limited reactivity of S-100 protein, cytokeratins, and/or desmin has also occasionally been reported.[
5] Diffuse positive expression of CD34, Bcl-2, and CD99 and negative expression of cytokeratin, α-SMA, S-100, CD31, and c-kit are useful in differentiating these entities. Electron microscopy shows fibroblast-like cells with well-developed rough endoplasmic reticulum, surrounded with collagen fibers.[
5] Histopathological examination, immunohistochemical study, and ultrastructural study are the key to diagnosis for SFT. Strong CD34 reactivity is currently regarded as characteristic and an indispensable finding in the diagnosis of SFT.[
5]
The differential diagnosis includes sarcomatoid renal cell carcinoma, angiomyolipoma, fibroma, and fibrosarcoma because these tumors typically show hemangiopericytomatous patterns.[
1] SFT is a rare tumor mimicking renal cell carcinoma and must be included in the differential diagnosis when a renal tumors consisting of mesenchymal elements are encountered. Roughly 10 to 15% of these tumors behave aggressively.[
1] The histopathologic features related to clinical malignancy include increased cellularity, pleomorphism, increased mitotic activity (>4 mitoses/10 high-power fields), necrosis, hemorrhage, and atypical location (parietal pleura, pulmonary parenchyma). However, the clinical behavior cannot be predicted on histopathological basis with benign-appearing tumors exhibiting aggressive behavior and vice versa. Therefore, all patients with these tumors need to be on long-term follow- up.[
1,
3]